We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-10.3%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.69B
AUM Growth
-$784M
Cap. Flow
+$36.9M
Cap. Flow %
1%
Top 10 Hldgs %
43.31%
Holding
160
New
14
Increased
20
Reduced
11
Closed
10

Top Buys

Rank Stock Value
1
EQRX
EQRx, Inc. Common Stock
EQRX
+$37.8M
2
KYMR icon
Kymera Therapeutics
KYMR
+$34.9M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$31.1M
4
EVO icon
Evotec
EVO
+$26.8M
5
BLU
BELLUS Health Inc.
BLU
+$21.6M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$172M
2
ARGX icon
argenx
ARGX
+$23.5M
3
ITOS
iTeos Therapeutics
ITOS
+$15M
4
BABA icon
Alibaba
BABA
+$14.8M
5
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 83.88%
2 Miscellaneous 7.67%
3 Consumer Discretionary 6.51%
4 Financials 0.7%
5 Materials 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBP
26
NovaBridge Biosciences American Depositary Shares
NBP
$184M
$40.3M 1.09%
850,000
+25,000
+3% +$1.5M
FHTX icon
27
Foghorn Therapeutics
FHTX
$246M
$39.4M 1.07%
1,720,720
– –
RUBY
28
DELISTED
Rubius Therapeutics, Inc
RUBY
$35.8M 0.97%
3,701,580
-454,045
-11% -$6.3M
NTLA icon
29
Intellia Therapeutics
NTLA
$1.58B
$32.5M 0.88%
275,000
– –
TRML
30
DELISTED
Tourmaline Bio
TRML
$31.6M 0.86%
206,426
– –
KLRS
31
Kalaris Therapeutics
KLRS
$77.4M
$30.1M 0.82%
101,016
– –
EVO icon
32
Evotec
EVO
$579M
$27.3M 0.74%
+1,149,425
New +$26.8M
EQRX
33
DELISTED
EQRx, Inc. Common Stock
EQRX
$27.3M 0.74%
+4,000,000
New +$37.8M
DNLI icon
34
Denali Therapeutics
DNLI
$3.26B
$26.8M 0.73%
600,000
+100,000
+20% +$4.74M
GOSS icon
35
Gossamer Bio
GOSS
$62.4M
$26.7M 0.72%
29,487
– –
OMGA
36
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$25.8M 0.7%
2,273,530
– –
ITOS
37
DELISTED
iTeos Therapeutics
ITOS
$25.3M 0.69%
544,047
-450,000
-45% -$15M
REPL icon
38
Replimune Group
REPL
$1.21B
$24.4M 0.66%
900,000
– –
SDGR icon
39
Schrodinger
SDGR
$1.72B
$24.4M 0.66%
700,000
– –
ATRA icon
40
Atara Biotherapeutics
ATRA
$92.4M
$23.6M 0.64%
60,000
– –
PRAX icon
41
Praxis Precision Medicines
PRAX
$8.72B
$23.6M 0.64%
80,000
– –
RLAY icon
42
Relay Therapeutics
RLAY
$4.12B
$23M 0.63%
750,000
+350,000
+88% +$11.1M
AUPH icon
43
Aurinia Pharmaceuticals
AUPH
$2.13B
$22.9M 0.62%
1,000,000
– –
VRTX icon
44
CALL
Vertex Pharmaceuticals
VRTX
$130B
$22M 0.6%
100,000
-100,000
-50% -$19.4M
KRON
45
DELISTED
Kronos Bio
KRON
$21M 0.57%
1,542,954
+225,000
+17% +$3.52M
AGEN
46
Agenus
AGEN
$318M
$20.9M 0.57%
331,175
+50,950
+18% +$4.02M
GBIO
47
DELISTED
Generation Bio
GBIO
$19.9M 0.54%
281,419
– –
AMAM
48
DELISTED
Ambrx Biopharma Inc
AMAM
$19.4M 0.53%
2,152,291
+1,302,291
+153% +$14.5M
IMA
49
ImageneBio Inc
IMA
$56.4M
$19.4M 0.53%
129,126
– –
NG icon
50
NovaGold Resources
NG
$3.18B
$17.8M 0.48%
2,600,000
– –
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q4 2021 Portfolio in Review

As of Q4 2021, Artal Group held 160 positions worth $3.69B, down 18% from $4.47B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Artal Group's Q4 2021 filing shows 14 new, 20 increased, 11 reduced and 10 closed positions. Its largest new stake was EQRx, Inc. Common Stock: 4,000,000 shares worth $27.3M. The largest sale was Acceleron Pharma, an estimated $172M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 83% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

  • Artal Group's largest Q4 2021 buy was EQRx, Inc. Common Stock: 4,000,000 shares worth $27.3M.
  • Artal Group added most to Kymera Therapeutics in Q4 2021, an estimated $34.9M increase.
  • Artal Group's biggest Q4 2021 reduction was argenx, cutting an estimated $23.5M.
  • Artal Group fully exited Acceleron Pharma in Q4 2021, selling an estimated $172M.
  • Artal Group's ten largest holdings make up 43% of its $3.69B portfolio in Q4 2021.
  • Artal Group opened 14 new positions and closed 10 in Q4 2021.
  • Artal Group's portfolio value fell 18% quarter-over-quarter to $3.69B.

Based on Artal Group's 13F filing for Q4 2021, filed 11 Feb 2022.